Clinical trial
Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph]…
NCT00063089 · Nabi Biopharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00063089 |
|---|---|
| Title | Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever |
| Official title | Initial Safety and Pharmacokinetics Trial of Immune Globulin to Staphylococcus Aureus Capsule Polysaccharide (Altastaph) in Subjects With S. Aureus Bacteremia and Persistent Fever |
| Lead sponsor | Nabi Biopharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Staphylococcal Infections |
| Intervention type | Drug |
| Interventions | S. aureus Immune Globulin Intravenous (Human) 5% |
| Enrollment | 40 |
| Start date | Sep 1, 2002 |
| Primary completion | Sep 1, 2004 |
| Completion | Sep 1, 2004 |
| First posted | Jun 20, 2003 |
| Last update posted | May 14, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: